Search
SOLACI Congress
HomePharmacologyAntiplatelet

Antiplatelet

View Category

Antiplatelet

ESC 2020 | Against the Grain, ASA Monotherapy Appears Superior after TAVR

After TAVR, patients with no anticoagulation indication are favored by monotherapy with aspirin (ASA) vs. dual antiaggregation...
solaci -
Learn More
Acute coronary syndromes

Can Aspirin Use Be Interrupted After Angioplasty?

Aspirin discontinuation 1 to 3 months after angioplasty with continued P2Y12 inhibitor therapy reduces the bleeding risk without...
solaci -
Learn More
Acute coronary syndromes

EuroPCR 2020 | FABOLUS FASTER: In the Quest for the Fastest, Most Potent Platelet Inhibition

This small study tested the pharmacodynamic effects of several antiplatelet agents. It concluded that tirofiban (Aggrastat) provides...
solaci -
Learn More
Antiplatelet

The FDA Approves Ticagrelor for Primary Prevention in High Risk Patients

The FDA has approved the indication of ticagrelor as primary prevention in high risk CAD patients with...
solaci -
Learn More
Acute coronary syndromes

Optimal Intervention Timing for NSTEMI with No Antiaggregant Pre-Treatment

Patients undergoing non-ST elevation MI (NSTEMI) who are not pre-treated with P2Y12 receptor inhibitors will benefit from...
solaci -
Learn More
Antiplatelet

Antiaggregation vs. Anticoagulation after Peripheral PCI

The truth is this question has no clear answer and what with do with peripheral stenting is...
solaci -
Learn More
Antiplatelet

Webinar SOLACI – 29/05 – Approach to Antiplatelet Therapy in Acute Coronary Syndrome

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be...
solaci -
Learn More
Acute coronary syndromes

Are Non-Culprit Lesions Really Innocent?

In recent times, a lot has been said about reducing the duration or intensity of antiplatelet therapy...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Dr. Omar Tupayachi - 0
Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Dr. Juan Manuel Pérez - 0
Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Dr. Juan Manuel Pérez - 0
Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Institutional News

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

solaci - 0
The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy